1. Home
  2. BEAM vs AMPX Comparison

BEAM vs AMPX Comparison

Compare BEAM & AMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$32.75

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Amprius Technologies Inc.

AMPX

Amprius Technologies Inc.

HOLD

Current Price

$11.57

Market Cap

2.4B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
AMPX
Founded
2017
2008
Country
United States
United States
Employees
N/A
109
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.4B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
AMPX
Price
$32.75
$11.57
Analyst Decision
Buy
Strong Buy
Analyst Count
12
7
Target Price
$50.75
$20.17
AVG Volume (30 Days)
2.6M
7.3M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$76.15
Revenue Next Year
$33.77
$59.65
P/E Ratio
N/A
N/A
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$6.09
52 Week High
$38.26
$24.23

Technical Indicators

Market Signals
Indicator
BEAM
AMPX
Relative Strength Index (RSI) 48.29 35.81
Support Level $23.83 $10.00
Resistance Level $35.18 $14.54
Average True Range (ATR) 2.84 1.16
MACD -0.06 -0.14
Stochastic Oscillator 21.32 6.39

Price Performance

Historical Comparison
BEAM
AMPX

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About AMPX Amprius Technologies Inc.

Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing processes leverage the manufacturing processes for conventional lithium-ion batteries and the related supply chain.

Share on Social Networks: